139 related articles for article (PubMed ID: 11762753)
1. A mathematical analysis of the interactions between immunogenic tumor cells and cytotoxic T lymphocytes.
Takayanagi T; Ohuchi A
Microbiol Immunol; 2001; 45(10):709-15. PubMed ID: 11762753
[TBL] [Abstract][Full Text] [Related]
2. Evasion of tumours from the control of the immune system: consequences of brief encounters.
Al-Tameemi M; Chaplain M; d'Onofrio A
Biol Direct; 2012 Sep; 7():31. PubMed ID: 23009638
[TBL] [Abstract][Full Text] [Related]
3. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression.
Yang D; Ud Din N; Browning DD; Abrams SI; Liu K
Clin Cancer Res; 2007 Sep; 13(17):5202-10. PubMed ID: 17785576
[TBL] [Abstract][Full Text] [Related]
4. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
[TBL] [Abstract][Full Text] [Related]
5. [Enhancement of Cytotoxic T Lymphocytes(CTLs)Infiltration into the Cancer Tissues].
Akazawa Y; Suzuki T; Nakatsura T
Gan To Kagaku Ryoho; 2018 Feb; 45(2):227-231. PubMed ID: 29483410
[TBL] [Abstract][Full Text] [Related]
6. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.
Sharma RK; Chheda ZS; Jala VR; Haribabu B
Expert Rev Vaccines; 2015 Apr; 14(4):537-49. PubMed ID: 25482400
[TBL] [Abstract][Full Text] [Related]
8. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
9. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
10. Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells.
Crowley NJ; Vervaert CE; Seigler HF
Cancer Res; 1992 Jan; 52(2):394-9. PubMed ID: 1728411
[TBL] [Abstract][Full Text] [Related]
11. CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes.
Shi L; Meng T; Zhao Z; Han J; Zhang W; Gao F; Cai J
Gene; 2017 Dec; 636():36-41. PubMed ID: 28888577
[TBL] [Abstract][Full Text] [Related]
12. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
13. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
15. Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.
Li A; Wu Y; Linnoila J; Pulli B; Wang C; Zeller M; Ali M; Lewandrowski GK; Li J; Tricot B; Keliher E; Wojtkiewicz GR; Fulci G; Feng X; Tannous BA; Yao Z; Chen JW
Cancer Immunol Immunother; 2016 Dec; 65(12):1545-1554. PubMed ID: 27722909
[TBL] [Abstract][Full Text] [Related]
16. Targeting p53 for adoptive T-cell immunotherapy.
McCarty TM; Liu X; Sun JY; Peralta EA; Diamond DJ; Ellenhorn JD
Cancer Res; 1998 Jun; 58(12):2601-5. PubMed ID: 9635585
[TBL] [Abstract][Full Text] [Related]
17. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
[TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
19. Macroimmunology and immunotherapy of cancer.
Hamilton D; Ismail N; Kroeger D; Rudulier C; Bretscher P
Immunotherapy; 2009 May; 1(3):367-83. PubMed ID: 20635957
[TBL] [Abstract][Full Text] [Related]
20. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
